Changing the Course of Outcomes in NSCLC: Immunotherapy Approaches for Early-Stage Disease

Join us for this live 1-hour, CME/CE/CPE-certified workshop to gain expert insights on emerging neoadjuvant/adjuvant immune checkpoint inhibitor–based regimens for the treatment of resectable stage I-III NSCLC. After the meeting, download the associated slideset for use in your clinic.


  • Welcome and Introduction
  • Rationale for Using Immune Checkpoint Inhibition in the Neoadjuvant/Adjuvant Setting for Early-Stage NSCLC
    • Overview of ICI-Based Therapy in the Management of Metastatic and Unresectable Stage III NSCLC
  • Emerging Role of ICI-Based Therapy in the Treatment of Resectable, Stage I-III NSCLC
    • Current Standards of Care
    • Clinical Data and Ongoing Trials in Adjuvant Setting
    • Clinical Data and Ongoing Trials in Neoadjuvant Setting
    • Identifying Optimal Candidates With Early-Stage Disease for ICI-Based Therapy
  • Management of Immune-Related Adverse Events
  • Audience Question and Answer Session


Date / Time
Event Details


Program Director
Justin F. Gainor, MD

Associate Professor
Department of Medicine
Harvard Medical School
Assistant in Medicine
Department of Medicine
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Boston, Massachusetts

Charu Aggarwal, MD, MPH

Leslye M. Heisler Associate Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Lyudmila Bazhenova, MD

Clinical Professor of Medicine 
Lung Cancer Unit Leader
Division of Hematology-Oncology
Department of Medicine
University of California, San Diego
San Diego, California

Narjust Florez, MD

Associate Director of the Cancer Care Equity Program
Thoracic Oncologist
The Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Boston, Massachusetts

Stephen V. Liu, MD

Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Sandip P. Patel, MD

Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California

Zofia Piotrowska, MD

Assistant Professor
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners in their understanding of the evidence and available data for patients with early-stage NSCLC and the emerging adjuvant and neoadjuvant options that will be available to them.

Target Audience
This program is intended for thoracic surgeons, oncologists, advanced practice providers, pharmacists, nurses, and other healthcare providers who care for patients with NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review diagnostic parameters that qualify patients for ICI-based neoadjuvant therapy
  • Analyze recent data to support novel therapeutic approaches vs standard of care
  • Examine ongoing clinical trials using immunotherapy in early-stage NSCLC
  • Plan therapy for patients with stage I-III NSCLC based on individual patient considerations, expert recommendations, and available clinical data


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

UAN for live meetings: JA4008176-0000-21-129-L01-P

UAN for simulcasts: JA4008176-0000-21-130-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.